Pulse Biosciences has made progress in treating Atrial Fibrillation using Nano PFA technology. Financially, they reported increased expenses in Q3 2024 but raised $60 million through a rights offering.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing